# Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct02072811/  
OnCo record `nct02072811` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cladribine, Daunorubicin and Mitoxantrone in Acute myeloid leukaemia, run by dr hab. n. med. Agnieszka Wierzbowska, with a status the registry has not verified recently.

## Summary

Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia is a phase 3 interventional study registered as NCT02072811 by dr hab. n. med. Agnieszka Wierzbowska, with 400 participants planned, started 2014-02 and due to reach its primary completion in 2018-02. Interventions recorded: DAC, CLAG, Consolidation, I HAM cycle, II Consolidation HiDAraC, Consolidation, III HiDAraC cycle. Conditions recorded: Acute Myeloid Leukemia.

Linked to the drug Cladribine because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02072811
- Phase: 3
- Setting: Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells
- Sponsor: dr hab. n. med. Agnieszka Wierzbowska
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT02072811: https://clinicaltrials.gov/study/NCT02072811

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Cladribine](https://onco.cc/drugs/cladribine/), [Daunorubicin](https://onco.cc/drugs/daunorubicin/), [Mitoxantrone](https://onco.cc/drugs/mitoxantrone/)

---
JSON: https://onco.cc/api/v1/entities/nct02072811.json